Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
20
×
boston top stories
bristol-myers squibb
20
×
national blog main
national top stories
new york blog main
life sciences
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
fda
pfizer
cancer
clinical trials
merck
celgene
eli lilly
abbvie
immunotherapy
medicare
amgen
astrazeneca
What
bio
roundup
drug
nash
news
annual
conference
new
pharmaceutical
week
approved
cancer
companies
days
disease
esmo
industry
liver
medical
medicine
people
policy
seven
alzheimer’s
american
approval
based
best
biogen
biogen’s
biotech
celgene
clinical
continue
crash
data
debate
drugs
european
fatty
Language
unset
Current search:
" bristol-myers squibb "
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M